Lyell Immunopharma (LYEL) Return on Capital Employed (2021 - 2025)
Historic Return on Capital Employed for Lyell Immunopharma (LYEL) over the last 5 years, with Q3 2025 value amounting to 0.94%.
- Lyell Immunopharma's Return on Capital Employed fell 5800.0% to 0.94% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.94%, marking a year-over-year decrease of 5800.0%. This contributed to the annual value of 0.63% for FY2024, which is 3300.0% down from last year.
- Per Lyell Immunopharma's latest filing, its Return on Capital Employed stood at 0.94% for Q3 2025, which was down 5800.0% from 0.96% recorded in Q2 2025.
- In the past 5 years, Lyell Immunopharma's Return on Capital Employed ranged from a high of 0.18% in Q3 2021 and a low of 0.96% during Q2 2025
- Moreover, its 5-year median value for Return on Capital Employed was 0.26% (2023), whereas its average is 0.4%.
- In the last 5 years, Lyell Immunopharma's Return on Capital Employed soared by 100bps in 2023 and then tumbled by -6100bps in 2025.
- Quarter analysis of 5 years shows Lyell Immunopharma's Return on Capital Employed stood at 0.19% in 2021, then dropped by -6bps to 0.2% in 2022, then plummeted by -65bps to 0.33% in 2023, then plummeted by -114bps to 0.72% in 2024, then tumbled by -31bps to 0.94% in 2025.
- Its last three reported values are 0.94% in Q3 2025, 0.96% for Q2 2025, and 0.86% during Q1 2025.